| Trial ID: | L4376 |
| Source ID: | NCT03122041
|
| Associated Drug: |
Sitagliptin
|
| Title: |
Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance and Type 2 Diabetes in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
PCOS
|
| Interventions: |
DRUG: Sitagliptin|BEHAVIORAL: Lifestyle intervention
|
| Outcome Measures: |
Primary: The main outcome was change in HOMA-β index (Homeostasis model assessment for beta cell function index)., Homeostasis model assessment for beta cell function index (HOMA-β) was calculated at the base point and after 12 weeks of clinical trial. | Secondary: The secondary outcome was change in fasting plasma glucose level (G0), Patient's fasting glucose level was measured at the base point and after 12 weeks of clinical trial.|The secondary outcome was change in plasma glucose level at 120 minutes (G120) after glucose load in oral glucose tolerant test (OGTT)., Patient's plasma glucose level at 120 minutes (G120) after glucose load in oral glucose tolerant test (OGTT) was measured at the base point and after 12 weeks of clinical trial.
|
| Sponsor/Collaborators: |
Sponsor: University Medical Centre Ljubljana
|
| Gender: |
FEMALE
|
| Age: |
ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
30
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION
|
| Start Date: |
2016-08
|
| Completion Date: |
2016-11
|
| Results First Posted: |
|
| Last Update Posted: |
2017-04-20
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT03122041
|
